Rallis India Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹456Cr
- +6% YoY
- −26.8% QoQ
- Net profit
- −₹15Cr
- Q4 FY25: −₹32 Cr
- Margin
- −0.2%
- +4.5 pp YoY
- −9.2 pp QoQ
Guidance rank: #20 of 23 in Fertilizers & Agrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Seeds business expected to deliver high double-digit growth next year, around mid to high teens, combining volume and price growth, driven by key crops: cotton, maize, millet, mustard, and rice. Seeds segment expected to deliver high double-digit growth (mid-teens) in next year driven by key crops: cotton, maize, millet, mustard, and rice.
From Rallis India Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Seeds business expected to deliver high double-digit growth next year, around mid to high teens, combining volume and price growth, driven by key crops: cotton, maize, millet, mustard, and rice.
- Crop Care segment sees focused growth in herbicides, soil & plant health, and seed sales rather than insecticides or diseases, with volume growth expected to be marginal positive in crop protection (low single digit).
- Aquafeed business is at an experimental stage with potential akin to soil and plant health 5-7 years ago; expected to need 1-2 more years to mature before scaling investments.
- Industry growth projected around 3-4% corresponding to GDP growth, with Rallis aiming for consistent and profitable growth through portfolio rationalization and market focus.
2 more points from Rallis India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rallis India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is investing in the aquafeed business, currently at an experimental stage with sales over INR 50 crores.
- They plan to evaluate this business for one more year before deciding on further investment.
- The aquafeed venture is seen as exciting and akin to the soil and plant health business 5-7 years ago, with potential for 1-2 more cycles before reaching scale.
- In seed R&D, rather than investing heavily in gene editing technology development in-house, Rallis prefers licensing technologies from global multinationals, leveraging their larger R&D.
2 more points from Rallis India Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rallis India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Rallis India Ltd — Quarterly revenue & net profit
Rallis India Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 456 | 430 | +6% | 623 | -26.8% |
| Operating profit (EBITDA) | -1 | -20 | — | 58 | -101.7% |
| Operating margin | -0.2% | -4.7% | +4.5 pp | 9% | -9.2 pp |
| Profit before tax | -17 | -40 | — | 1 | -1800% |
| Net profit (PAT) | -15 | -32 | — | 2 | -850% |
| EPS (₹) | -0.77 | -1.65 | — | 0.10 | -870% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹858 Cr, net profit ₹85 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rallis India's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Rama Phosphates (Q4 FY26)
Revenue grew by 20% year-on-year (Page 8). Key investor presentation takeaways from Rama Phosphates's Q4 FY26 investor presentation — and how it ranks against s
- Khaitan Chemical (Q4 FY26)
Q4-FY26 Operational Revenue: INR 1,930 million, up 20.1% YoY (from INR 1,607 million in Q4-FY25). Key investor presentation takeaways from Khaitan Chemical's Q4
- Dhansa Labs (Q4 FY26)
120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…
- Advance Agrolife (Q4 FY26)
Q4 FY26 total revenue: ₹1,259.07 million, up 40% YoY (Page 24). Key concall takeaways from Advance Agrolife Ltd's Q4 FY26 earnings call — and how it ranks…
Potential multibaggers · Q2 FY27
Potential multibaggers in Fertilizers & Agrochemicals
on management's own guidance
- Insecticides IndiaGood growth2
- Anya Polytech &Good growth1
- Madhya Bharat Agro ProductsGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rallis India Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rallis India Ltd Q4 FY26 results?
Seeds business expected to deliver high double-digit growth next year, around mid to high teens, combining volume and price growth, driven by key crops: cotton, maize, millet, mustard, and rice. Seeds segment expected to deliver high double-digit growth (mid-teens) in next year driven by key crops: cotton, maize, millet, mustard, and rice.
What is Rallis India Ltd share price analysis?
Rallis India Ltd currently shows a neutral. The stock trades at a P/E of 18.4 with a market cap of ₹4,208 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rallis India Ltd planning capital expenditure?
The company is investing in the aquafeed business, currently at an experimental stage with sales over INR 50 crores.
Keep Rallis India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
